Slide 1: Web conference – Q4 sales
Web conference – Q4 sales January 16, 2025 1
Slide 2: Participants from Oncopeptides
Participants from Oncopeptides • Sofia Heigis, CEO • Henrik Bergentoft, CFO 2
Slide 3: What have we announced?
What have we announced? • Q4 sales figure (18.6 mSEK). • Updated cash-flow expectations (2027). • Progress in Japan discussions. • Sharpened focus in Germany. • Glioblastoma an emerging opportunity. 3
Slide 4: Where we are right now
Where we are right now Q4 2024 Q4 2025 9.9 mSEK 18.6 mSEK 4
Slide 5: Our potential
Our potential Financial potential € Pepaxti Rest of World in Europe Pipeline partnerships Transformative Commercial Licensing base potential upside Now Long-term A global biotech with a marketed product, expanding indications, and a proprietary platform unlocking future therapies 5
Slide 6: Drivers of European growth
Drivers of European growth 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2023 2023 2023 2023 2024 2024 2024 2024 2025 2025 2025 2025 Revenue, European sales, million SEK 6
Slide 7: European commercialization
European commercialization
Slide 8: Our ambition: launch as fast as possible with a price reflecting our innovation
Our ambition: launch as fast as possible with a price reflecting our innovation – providing patient and shareholder value. 8
Slide 9: Europe
Q4 2025 Europe Q4 2024 9
Slide 10: Spain
Q4 2025 Spain Q4 2024 10
Slide 11: Germany
Q4 2025 Germany Q4 2024 11
Slide 12: Italy
é (Ces . Perug® ITALY @ ee
Slide 13: European commercialization
European commercialization Phase I – completed ≈55% Phase II – completed Market exclusivity until Phase II – pending 2037 ≈35% Phase III ≈10% Phase IV % of market potential per phase out of SEK ≈1.5 billion estimated annual market potential. 13
Slide 14: Partnerships
Partnerships
Slide 15: Pepaxti commercialization and partnership landscape
Pepaxti commercialization and partnership landscape Oncopeptides’ expansion Reimbursed strategy can be summarized Available via partner as: grow geographically, Market access pending partner smartly, and Regulatory process ongoing by partner innovate purposefully. Partnership discussion ongoing 15
Slide 16: Japan partnership potential
Japan partnership potential Growing Fast market Comparable to patient access German market population potential Favorable High unmet regulatory need in 4L+ landscape setting 16
Slide 17: Beyond Multiple Myeloma
Beyond Multiple Myeloma
Slide 18: Glioblastoma
Glioblastoma
Slide 19: Glioblastoma: brain tumor with high unmet need & growing market potential
Glioblastoma: brain tumor with high unmet need & growing market potential Most aggressive brain cancer – grows fast, invariably relapses, and has no cure. Rare but severe – affects about 2–3 people per 100,000 each year, usually above the age of 60. Glioblastoma Poor survival – even with treatment,
Slide 20: PDCs have potential to help patients with brain tumors, such as glioblastoma
PDCs have potential to help patients with brain tumors, such as glioblastoma Reminder: Critical BBB passage confirmed • OPD5 has shown promising preclinical data • OPD5 has shown an efficient blood-brain barrier penetration and strong tumor reduction in preclinical models 20
Slide 21: Glioblastoma market potential
Global Market Value 2024 Glioblastoma market potential Global Market Value 2035 $8.15B- $8.3B Fast-to-market opportunity • High unmet medical need and very modest efficacy of existing therapies $3.6- • High probability of an accelerated approval based on single-arm Ph1/2 $3.9B data in relapsed gliob
Slide 22: Summary: OPD5 in glioblastoma
Summary: OPD5 in glioblastoma Strong therapeutic Very high unmet Potential for rationale need and market accelerated and differentiated potential approval mode of action 22
Slide 23: In closing
In closing
Slide 24: Reasons to believe
Reasons to believe Europe RoW Pipeline SEK ≈1.5 billion/year Opportunities outside Strengthened market potential of key markets remain opportunity in strong pipeline value drivers 24
Slide 25: Oncopeptides
e@ oncopeptides —_
Slide 26: Bringing hope through science
Bringing hope through science